The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback